An observed signal for cardiac dysfunction in the Lenvatinib-Belzutifan arm of a recent trial is causing concern among clinicians. The lack of detailed characterization for this toxicity makes it a significant point of discussion and an area requiring more data before the regimen's safety profile is fully understood.

Data on Enfortumab Vedotin suggests that for modern therapies, maintaining patients on treatment longer via a lower, more tolerable starting dose is more important than administering the maximum labeled dose upfront, a concept inherited from the cytotoxic chemotherapy era.

Contrary to the assumption that two drugs are always more toxic than one, the Lenvatinib-Belzutifan combination in the LightSpark-011 trial presented a different, but not quantifiably worse, toxicity profile compared to cabozantinib monotherapy, challenging conventional thinking on combination therapy side effects.

The Phase 2 TRAIT study suggests starting adjuvant abemaciclib at a lower dose and escalating over several weeks significantly reduces early discontinuations due to side effects like diarrhea. This strategy helps more patients get through the initial high-toxicity period and remain on the effective dose for the full two-year course.

A key nuance in managing ponatinib for Ph+ ALL is a response-adapted dosing strategy. Patients are typically started at a 30mg dose, which is then reduced to 15mg once a good minimal residual disease (MRD) response is achieved. This approach aims to maintain efficacy while mitigating long-term toxicity.

For older, transplant-ineligible myeloma patients, quadruplet regimens are not administered at full strength. Clinicians proactively reduce doses of bortezomib, lenalidomide, and dexamethasone based on patient fitness and renal function to manage toxicity while maintaining efficacy.

Concerns over arterial events caused physicians to start CML patients on lower, less effective doses of ponatinib. Data shows a start-high (45mg) then reduce strategy is more effective for disease control and safely mitigates side effect risks, contrary to clinical practice.

A majority of patients on the lenvatinib/pembrolizumab regimen require dose reductions due to toxicity. Crucially, clinical trial data shows no significant change in progression-free survival for patients on lower doses, an important point for patient reassurance.

Contrary to the assumption that combinations are more toxic, Lenvatinib/Belzutifan showed a different side effect profile, not a worse one, compared to single-agent Cabozantinib. The combo caused more anemia while Cabozantinib caused more diarrhea and skin toxicity, but treatment discontinuation rates were identical at 11% for both arms.